Skip to main content
. 2020 Mar 25;10(20):12089–12104. doi: 10.1039/d0ra01002b

The in vitro bioactivities and stabilities of 1a–1i.

Peptide EC50a (nM) Plasma half-lifeb (h) Peptide EC50a (nM) Plasma half-lifeb (h)
Lixisenatide 0.076 ± 0.013 7.1 1e 0.13 ± 0.03 21.2
1a 0.19 ± 0.02 13.2 1f 0.32 ± 0.13 33.4
1b 0.49 ± 0.11 19.1 1g 0.59 ± 0.16 11.9
1c 0.98 ± 0.24 30.0 1h 1.97 ± 0.53 17.8
1d 0.085 ± 0.021 13.1 1i 4.68 ± 0.85 31.6
a

Data are represented as EC50. Values are the means ± SD from three independent experiments.

b

The plasma half-lives of lixisenatide and 1a–1i were calculated after incubation of peptides in rat plasma over 48 h.